Veeva Systems (VEEV) Q2 2026 Earnings Call August 27, 2025 05:00 PM ET Company ParticipantsGunnar Hansen - Director of IRPeter Gassner - Founder, CEO & DirectorBrian Van Wagener - CFOPaul Shawah - EVP, Commercial StrategyBrian Peterson - Managing DirectorDavid Windley - Managing DirectorRishi Jaluria - MD & Software Equity ResearchCraig Hettenbach - Executive DirectorJailendra Singh - Managing DirectorSaket Kalia - Managing DirectorJeff Garro - Managing DirectorDavid Larsen - Managing DirectorConference Cal ...

Financial Data and Key Metrics Changes - Total revenue for the quarter was $789 million, with non-GAAP operating income of $353 million, exceeding guidance [6][7]. - The company expressed confidence in its $6 billion revenue plan over the next five years, indicating strong performance and growth potential [22]. Business Line Data and Key Metrics Changes - R&D subscriptions and services showed significant upside, indicating a broad-based growth across all areas [19][40]. - The resolution of the lawsuit with IQVIA is expected to enhance the commercial cloud offerings, particularly in integrating IQVIA data into Veeva's products [12][14]. Market Data and Key Metrics Changes - The company reported strong execution across its business segments, with no specific areas of weakness despite macroeconomic uncertainties [124]. - The commercial cloud segment is anticipated to benefit from the resolution with IQVIA, allowing for a more comprehensive solution for customers [73][86]. Company Strategy and Development Direction - Veeva is focusing on enhancing its AI capabilities, with plans to integrate AI agents into its existing platforms, which is expected to create significant value for the industry over time [28][30]. - The company aims to leverage its structural advantages in the life sciences sector to lead in industry-specific cloud applications and AI agents [46][48]. Management's Comments on Operating Environment and Future Outlook - Management noted that while there is elevated uncertainty in the macro environment, customer engagement remains strong, and the pipeline is building effectively [124]. - The company does not expect immediate revenue contributions from the IQVIA resolution but sees it as a long-term growth driver [90]. Other Important Information - The company is working on refining its migration tooling to facilitate customer transitions to the Vault CRM, with over 20 customers already migrated and 300 more planned [106]. - Veeva's business consulting services are seen as a critical component in driving AI adoption and helping customers navigate changes in workflows [111][115]. Q&A Session Summary Question: What led to the resolution of the lawsuit with IQVIA? - The resolution was driven by changes in the industry landscape and a mutual recognition that collaboration would benefit both companies and their customers [12][14]. Question: How does the resolution with IQVIA unlock new opportunities? - It removes previous barriers to integrating IQVIA data into Veeva's products, enhancing the commercial cloud offerings and allowing for more comprehensive solutions [14][73]. Question: What is the outlook for R&D subscription growth? - R&D subscriptions are expected to continue growing, supported by strong execution across all areas and a stable environment [40][76]. Question: How does Veeva plan to leverage AI in its offerings? - Veeva plans to integrate AI agents into its platforms, enhancing productivity and creating new revenue opportunities over time [28][30]. Question: What is the customer reaction to the IQVIA resolution? - Customer feedback has been overwhelmingly positive, as the resolution alleviates previous integration issues and opens up new possibilities for collaboration [34][36]. Question: What are the expectations for commercial subscriptions moving forward? - The company anticipates continued strength in commercial subscriptions, particularly driven by the Crossix product, despite some flatness in the recent quarter [74][76]. Question: How does Veeva differentiate itself in the AI space? - Veeva's structural advantage lies in its deep industry-specific applications, allowing for seamless integration of AI agents into existing workflows [94][96].

Core Insights - Veeva Systems is hosting the Veeva R&D and Quality Summit on September 3-4, 2025, in Boston, featuring leaders from major biopharmaceutical companies like BeOne Medicines, Intercept Pharmaceuticals, Merck, and Pfizer to discuss advancements in clinical, regulatory, safety, and quality processes [1][5] Group 1: Event Highlights - The summit will showcase over 100 sessions focused on the latest advancements in life sciences, including strategies for accelerating development and manufacturing by connecting systems and processes [3] - Key topics include improving trial oversight and collaboration among sites, sponsors, and CROs [4] Group 2: Innovations and Technologies - Veeva will highlight its advancements in software, data, and business consulting, particularly the integration of Veeva AI into the Vault Platform, which provides secure access to data and workflows [2] - The event will feature discussions on how customers can leverage Veeva AI to create custom agents tailored to their needs [2] Group 3: Industry Engagement - The summit aims to foster an environment of openness where industry leaders can share experiences and ideas to expedite the delivery of medicines to patients [5] - More than 2,000 attendees are expected, all of whom are life sciences professionals [6] Group 4: Company Overview - Veeva Systems is recognized as a global leader in cloud software for the life sciences industry, serving over 1,000 customers, including large biopharmaceutical companies and emerging biotechs [7]

Core Insights - Veeva Systems Inc. (VEEV) is positioned for growth due to its strong product portfolio and solid first-quarter fiscal 2026 performance, despite concerns over rising operational costs [1][12]. Financial Performance - Veeva's shares have increased by 31.7% year-to-date, outperforming the industry growth of 19.9% and contrasting with the S&P 500's decline of 8.5% [2]. - The company has a market capitalization of $46.1 billion and anticipates a growth rate of 26.2% over the next five years, with a trailing four-quarter average earnings surprise of 10% [3]. Product and Service Developments - Veeva continues to drive the adoption of its next-gen Vault CRM, with 20 new customers, particularly from small and mid-sized biotech firms [5]. - The introduction of AI-driven innovations, such as CRM Voice Control and MLR Bot, aims to enhance efficiency and compliance [6]. - Veeva's Data Cloud solutions are gaining traction, with significant contracts and partnerships, including a long-term collaboration with Walgreens Boots Alliance [7][9]. Strategic Initiatives - The company has secured key deals, including Boehringer Ingelheim's migration to Veeva Vault CRM and partnerships to enhance generative AI capabilities [9]. - Veeva's first-quarter fiscal 2026 results exceeded expectations, driven by strong performance in subscription and professional services [10]. Cost Management - Operating costs have risen, with general and administrative expenses increasing by 12.3% year-over-year in the first quarter of fiscal 2026 [12]. - Total operating expenses increased by 9.4% year-over-year, with expectations for further increases due to employee compensation-related costs [13]. Future Outlook - The Zacks Consensus Estimate for fiscal 2026 earnings per share has increased by 3 cents to $7.64, with second-quarter revenue estimates indicating a 13.5% improvement year-over-year [14].

Core Insights - Veeva Systems is launching Veeva AI, a generative AI layer integrated into its Vault platform to enhance automation and efficiency for life sciences companies [1][6] - The integration of AI aims to improve productivity and decision-making in clinical, quality, and regulatory functions, thereby increasing customer reliance on Veeva's software [2][6] - Veeva is experiencing steady financial performance and geographic expansion, particularly in China, positioning itself as a key technology provider as life sciences firms adopt AI [2] Competitive Landscape - IQVIA Holdings is also investing in AI, utilizing its Orchestrated Clinical Trials platform to enhance trial planning and patient recruitment, showcasing a different approach by combining data, analytics, and services [3] - Schrodinger Inc. is leveraging AI in drug discovery, focusing on deep learning and molecular simulation to optimize drug compounds, thus complementing Veeva's offerings in the life sciences ecosystem [4] Financial Performance - Veeva's shares have increased by 34.6% year-to-date, outperforming the industry growth of 22.5% [5][6] - The company has a forward price-to-sales ratio of 14.25, which is above the industry average, indicating a premium valuation [8] - The Zacks Consensus Estimate predicts a 15.8% rise in Veeva's fiscal 2026 earnings compared to the previous year [9]

Core Insights - Veeva Systems Inc. reported total revenues of $759.0 million for the first quarter of fiscal 2026, representing a 17% increase year over year [1][6] - Subscription services revenues reached $634.8 million, up 19% from the previous year [1][6] - The company achieved a revenue run rate goal of $3 billion for 2025, indicating strong growth and innovation [6] Financial Performance - Operating income for the first quarter was $233.7 million, a 51% increase from $155.2 million a year ago [6] - Non-GAAP operating income was $349.9 million, up 34% from $260.9 million year over year [6] - Net income for the quarter was $228.2 million, a 41% increase compared to $161.7 million in the same period last year [6] - Non-GAAP net income was $327.8 million, reflecting a 33% increase from $247.0 million year over year [6] - Fully diluted net income per share was $1.37, compared to $0.98 a year ago, while non-GAAP fully diluted net income per share was $1.97, up from $1.50 [6] Strategic Initiatives - Veeva AI is set to enhance productivity and automation in the life sciences sector, with its first release planned for December 2025 [6] - The company showcased innovations at the Commercial Summit, including AI Agents aimed at improving operational efficiency [6] - Veeva expanded its commercial data offerings with the launch of Veeva CRM Pulse, enhancing its data cloud capabilities [6] Guidance and Outlook - For the fiscal second quarter ending July 31, 2025, Veeva expects total revenues between $766 million and $769 million [6] - The company anticipates non-GAAP operating income between $335 million and $337 million for the same period [6] - For the fiscal year ending January 31, 2026, Veeva projects total revenues between $3,090 million and $3,100 million [6]

Group 1: Marvell Technology Group Ltd. (MRVL) - Marvell Technology has seen its stock price drop 50% from January peaks ahead of its Q1 FY26 earnings release due to disappointing revenue forecasts and broader semiconductor sector weakness [2][3] - The company's valuation needed a reset after trading as high as 83X forward earnings last year, and it is currently trading at a 30% discount to its 10-year median [3][6] - Marvell's data center revenue surged 78% in Q4, driven by the AI spending boom, and it is projected to grow revenue by 44% this year and 18% next year [4][6] - Despite the recent downturn, Wall Street remains bullish on Marvell, with 25 of 31 brokerage recommendations rated as "Strong Buys" [7] Group 2: Veeva Systems (VEEV) - Veeva Systems, a cloud-based software company for the pharmaceutical and life sciences industries, has averaged 25% revenue growth over the last decade and its stock has surged 760% [9][12] - The company trades 30% below its 2021 peaks, with concerns about slowing growth and valuation impacting its stock price [12][20] - Veeva's revenue grew by 16% in fiscal 2025, driven by a 20% increase in subscription services, and it is projected to grow revenue by 11% this year and 12% next year [16][18] - The company has $5.1 billion in cash and equivalents, with minimal debt, allowing it to pursue growth opportunities and acquisitions [21]

Core Insights - Veeva Systems has launched Veeva AI, an initiative to integrate AI into the Veeva Vault Platform and applications, aimed at automating industry-specific functions and enhancing productivity across various sectors from clinical to commercial [1][5] - Veeva AI utilizes large language models (LLMs) to create application-specific AI Agents and AI Shortcuts, enabling life sciences companies to streamline tasks and improve employee efficiency [1][2] Veeva AI Features - Veeva AI Agents can be quickly deployed with high impact due to their understanding of Veeva application context, application-specific prompts, and secure access to application data and workflows [2] - Customers have the flexibility to configure Veeva-delivered AI Agents or develop custom AI Agents tailored to specific use cases, accessible via a chatbot interface or AI API [2] User Empowerment - Veeva AI Shortcuts allow end users to set up personal AI-powered automations for frequent tasks, such as workflow assistance, generating insights, or conducting research [3] Strategic Vision - Veeva's CEO, Peter Gassner, emphasized that the integration of GenAI with core applications will significantly enhance productivity for knowledge workers by providing human-like capabilities to derive insights from complex data [4] - Veeva AI is designed to be LLM agnostic, supporting various major LLMs, and ensuring customer data security regardless of the LLM used [4] Market Positioning - The first release of Veeva AI is scheduled for December 2025, with a subscription model aimed at promoting broad and thoughtful industry adoption [5] - Veeva serves over 1,000 customers in the life sciences sector, including major biopharmaceutical companies and emerging biotechs, highlighting its leadership in cloud software solutions [6]